Ate-Bev Early Response Prediction Model in Advanced HCC

Developing Atezolizumab-Bevacizumab Treatment Response Early Prediction Model in Advanced Hepatocellular Carcinoma Patients

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05763277

Enrollment

170

Registered

2023-03-10

Start date

2022-07-22

Completion date

2026-12-31

Last updated

2025-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atezolizumab-bevacizumab, Hepatocellular Carcinoma, Response Evaluation

Brief summary

The prognosis of hepatocellular carcinoma is poor compared to other carcinomas. Many drugs have recently been developed, and recently, atezolizumab-bevacizumab treatment was superior to sorafenib, the conventional treatment for advanced hepatocellular carcinoma. However, there is no information on the evaluation on the evaluation of treatment response for atezolizumab-bevacizumab combination therapy compared to atezolizumab alone or bevacizumab alone. Therefore, this study aimed to create a predictive model that can detect treatment response at an early stage.

Interventions

DIAGNOSTIC_TESTEarly response evaluation

Atezolizumab and bevacizumab are administered every three weeks, and before to the second treatment cycle, blood tests and imaging tests are conducted (week 5). This precedes the standard response evaluation (week 9-12).

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Yes

Inclusion criteria

* Patients who were diagnosed with advanced hepatocellular carcinoma and who were scheduled to receive atezolizumab-bevacizumab as the first-line therapy * Patients willing to participate in this study

Exclusion criteria

* Individuals with a history of severe contrast allergy * Individuals with severe comorbidities (according to the American Society of Clinical Oncology-Friends of Cancer Research Organ Dysfunction.)

Design outcomes

Primary

Measure	Time frame	Description
progression free survival	the follow up will be continued until June 22th 2025.	the index date is the date of treatment with atezolizumab and bevacizumab, and the event is either death or tumor progression of the tumor.

Secondary

Measure	Time frame	Description
Overall survival	the follow up will be continued until June 22th 2025.	the index date is the date of treatment with atezolizumab and bevacizumab, and the event is death.

Countries

South Korea

Contacts

Primary ContactJeong-Hoon Lee, MD PhD

pindra@empal.com+82-2-2072-2228

Backup ContactHyunjae Shin, MD

yhstella@gmail.com+82-2-2072-2228

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026